New Options for Overcoming Resistance to Anti-VEGF Therapy in HCC
Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shares his expert opinion on the importance of the phase III IMbrave150 trial, which evaluated a targeted therapy combination in patients with hepatocellular carcinoma.<br />
Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell,shares his expert opinion on the importance of the phase III IMbrave150 trial (NCT03434379), which evaluated a targeted therapy combination in patients with hepatocellular carcinoma (HCC).
The IMbrave150 trialis interesting because it allows the field to move beyond sorafenib (Nexavar) and nivolumab (Opdivo), 2 targeted agents that have been approved by the FDA under certain indications for HCC, says Saif. Because HCC is an intense disease, it is sometimes necessary to use more than 1 drug to treat the disease. In IMbrave150, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) is compared to sorafenib in patients with untreated locally advanced or metastatic HCC.
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
